Transgenic plant-derived pharmaceuticals - the practical approach?

Expert Opin Biol Ther. 2004 Oct;4(10):1565-8. doi: 10.1517/14712598.4.10.1565.

Abstract

Production of biopharmaceuticals in transgenic plants would involve the creation of a new industry. Those transgenic plants, including staple food crops, could provide many benefits to people all over the world. However, the new industry might require a strict regulation system. It is probable that such a strict system would not be acceptable to Japan or to most developing countries. Many countries should use non-food crops for production of biopharmaceuticals and take on more simple systems. The new industry must develop strategies for promoting the benefits of transgenic plant-derived biopharmaceuticals on both the domestic and worldwide scales.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / biosynthesis
  • Antibodies, Monoclonal / isolation & purification
  • DNA, Recombinant / genetics
  • Drug Contamination / prevention & control
  • Drug Design
  • Genetic Engineering
  • Humans
  • Pharmaceutical Preparations / isolation & purification*
  • Plants, Genetically Modified* / chemistry
  • Protein Processing, Post-Translational
  • Recombinant Fusion Proteins / biosynthesis
  • Recombinant Fusion Proteins / isolation & purification
  • Safety
  • Technology, Pharmaceutical / methods*

Substances

  • Antibodies, Monoclonal
  • DNA, Recombinant
  • Pharmaceutical Preparations
  • Recombinant Fusion Proteins